SAGA Diagnostics AB, a Sweden-based cancer liquid biopsy and genomic testing company, announced on Thursday that it has named Peter Collins as its new chief executive officer.
Collins is a highly experienced entrepreneur with more than 30 years of experience in the pharma and diagnostics sector. He has served as chief business officer at Inivata, VP Biopharma Business Development at Guardant Health, CBO of Yourgene, and VP, head of Diagnostics at GSK.
Collins said, 'SAGA is an outstanding company with a leading technology and solid market traction. Ultrasensitivity and detection of minimal residual disease (MRD) is exactly what biopharma, the clinical testing market and cancer patients need. SAGA has a diverse and exceptionally talented team already in place – I'm excited to lead this next phase of growth, build out the team further, and execute on a strategy to rapidly bring our technologies into the clinics to benefit more people living with cancer.'
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer